Leerink initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $5 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Ovid Therapeutics Reports Q3 2025 Financial Results
- Ovid Therapeutics reports Q3 EPS (17c), consensus (15c)
- Ovid Therapeutics appoints Alexander as CEO, Levin as Executive Chairman
- Ovid Therapeutics (OVID) Q3 Earnings Cheat Sheet